Federal Republic of Germany: Neuroleptic Relapse Prevention

  • W. Kissling
Conference paper

Abstract

The current state of relapse prevention in schizophrenia is very unsatisfactory. Under routine treatment conditions 50% of our schizophrenic patients suffer a relapse within one year of their most recent episode (Gaebel and Pietzcker 1985). Patients with first episode schizophrenia must be readmitted to inpatient treatment an average of two times during the 5 year period following their first episode and spend an average of 300 days in the hospital during this time (Maurer and Biehl 1988). Approximately 70% of all hospitalized schizophrenic patients are readmissions (Kissling et al. 1990).

Keywords

Schizophrenic Patient Relapse Prevention Recent Episode Neuroleptic Treatment Fluphenazine Decanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bäuml J, Wais A, Meurer T, Kissling W (1988) Compliance improvement with a long-term treatment of schizophrenic patients through a specific educational program for relatives. Psychopharmacology 96:223Google Scholar
  2. Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  3. Gaebel W, Pietzcker A (1983) Indikation zur neuroleptischen Langzeitmedikation — Standardverfahren oder individualprognostisch geleitete Intervention? Nervenarzt 54:467–476PubMedGoogle Scholar
  4. Gaebel W, Pietzcker A (1985) One-year outcome of schizophrenic patients — the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 18:235–239PubMedCrossRefGoogle Scholar
  5. Helmchen H (1979) Neuroleptische Langzeitmedikation in der Praxis. Mkurse Ärztl Fortbild 29:800–801Google Scholar
  6. Kane JM (1985) Compliance issues in outpatient treatment. J Clin Psychopharmacol 5:22–27CrossRefGoogle Scholar
  7. Kissling W (1988) Consensus regarding indication for prophylactic neuroleptic treatment -necessary, but unattainable? In: Barnes TRE (ed) Depot neuroleptics: a consensus. Mediscript, LondonGoogle Scholar
  8. Kissling W, Möller HJ, Bäuml J, Dietzfelbinger T, Winter I (1990) Fluanxol Depot 10% versus Haloperidol-Decanoat. Dosierung und Applikationsintervalle. In: Müller-Oerlinghausen B, Möller HJ, Rüther E (eds) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New YorkGoogle Scholar
  9. Lewandowski L, Buchkremer G (1988) Therapeutische Gruppenarbeit mit Angehörigen schizophrener Patienten. Z Klin Psychol 17:210–224Google Scholar
  10. Lungershausen E (1981) Probleme der neuroleptischen Langzeitbehandlung bei schizophrenen Erkrankungen. pmi-pharm, FrankfurtGoogle Scholar
  11. Maurer K, Biehl H (1988) Klinikaufenthalte und produktive Rückfälle bei ersterkrankten Schizophrenen. Determinanten des Zeitverlaufs zwischen stationären Aufnahmen bzw. schizophrenen Rezidiven über fünf Jahre. Nervenheilkunde 7:279–290Google Scholar
  12. Müller P (1983) Was sollen wir Schizophrenen raten: medikamentöse Langzeitprophylaxe oder Intervallbehandlung? Nervenarzt 54:477–485PubMedGoogle Scholar
  13. Nedopil N, Rüther E, Hippius H (1982) Neue Aspekte der Neuroleptika-Therapie. Schwerpunkt-med 5(2):25–29Google Scholar
  14. Schüssler G (1985) Medikamentöse Behandlung von schizophrenen Patienten in der nervenärztlichen Praxis. In: Linden M, Lipski C, Pietzcker A (eds) Der schizophrene Patient in der Nervenarztpraxis. Thieme, StuttgartGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • W. Kissling

There are no affiliations available

Personalised recommendations